A Phase 4 interventional study of pramipexole in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 99 sites in 10 countries. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-05-16.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 4th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 4, and was the 6th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 535 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2006, is one of 7 in phase 4, and was the 7th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
Drug: pramipexole
Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
Drug: pramipexole
Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Time frame: Baseline and Month 9
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Time frame: Baseline and Month 6
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Time frame: Baseline and Month 3
Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Time frame: Baseline and Month 9
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Time frame: Baseline and Month 6
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Time frame: Baseline and Month 3
Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Time frame: Baseline and Month 9
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Time frame: Baseline and Month 6
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Time frame: Baseline and Month 3
Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Time frame: Baseline and Month 9
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Time frame: Baseline and Month 6
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Time frame: Baseline and Month 3
Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Time frame: Baseline and Month 15
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Time frame: Baseline and Month 9
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Time frame: Baseline and Month 6
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Time frame: Baseline and Month 3
Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15
The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse). Responders are defined as those patients with a CGI-I of 1 or 2.
Time frame: Month 15
Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15
The CGI-S measures the participants severity of illness on an ordinal scale ranging from 1 (normal) to 7 (extremely ill). At Month 15 participants were categorised to 'Improved' (\>1 category improvement), 'Unchanged' or 'Worsened' (\>1 category worsening).
Time frame: Baseline and Month 15
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Time frame: Baseline and Month 15
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Time frame: Baseline and Month 9
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Time frame: Baseline and Month 6
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Time frame: Baseline and Month 3
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15
The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
Time frame: Baseline and Month 15
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9
The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
Time frame: Baseline and Month 9
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15
The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
Time frame: Baseline and Month 15
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9
The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
Time frame: Baseline and Month 9
Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15
The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
Time frame: Baseline and Month 15
Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9
The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
Time frame: Baseline and Month 9
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Time frame: Month 1
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Time frame: Month 6
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Time frame: Month 9
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Time frame: Month 12
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Time frame: Month 15
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Time frame: Month 1
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Time frame: Month 6
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Time frame: Month 9
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Time frame: Month 12
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Time frame: Month 15
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Time frame: Month 1
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Time frame: Month 6
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Time frame: Month 9
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Time frame: Month 12
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Time frame: Month 15
Percentage Change From Baseline in the Striatum Uptake at Month 15
The striatum beta-carbomethoxy-iodophenyl-tropane (beta-CIT) uptake was calculated as mean of the left and right caudate and putamen regions; measured by the Single-Photon Emission Computed Tomography (SPECT).
Time frame: Baseline and Month 15
Clinically Significant Abnormalities in Clinical Laboratory Measurements - Haematology and Electrolytes
Time frame: Baseline and Month 15
Clinically Significant Abnormalities in Clinical Laboratory Measurements - Enzymes
Time frame: Baseline and Month 15
Clinically Significant Abnormalities in Clinical Laboratory Measurements - Substrates
Time frame: Baseline and Month 15
Clinically Significant Abnormalities in Vital Signs
Time frame: Baseline and Month 15
| Milestone | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Started | 261 | 274 |
| Completed | 198 | 192 |
| Not completed | 63 | 82 |
| Withdrew: Adverse event | 41 | 43 |
| Withdrew: Lack of efficacy | 9 | 14 |
| Withdrew: Protocol violation | 6 | 5 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 6 | 17 |
| Withdrew: Other | 1 | 1 |
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15 | 0.3 ± 0.7 | 0.7 ± 0.7 |
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15 | 0.6 ± 0.7 | 0.5 ± 0.7 |
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9 | -0.5 ± 0.6 | 4.3 ± 0.6 |
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6 | -1.8 ± 0.6 | 2.6 ± 0.6 |
The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3 | -2.9 ± 0.5 | -0.1 ± 0.5 |
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15 | 0.6 ± 0.7 | 0.7 ± 0.7 |
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15 | 0.8 ± 0.7 | 0.6 ± 0.7 |
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9 | -0.3 ± 0.6 | 4.2 ± 0.6 |
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6 | -1.5 ± 0.6 | 2.5 ± 0.6 |
The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3 | -2.8 ± 0.5 | 0.0 ± 0.5 |
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15 | 0.1 ± 0.5 | 0.3 ± 0.5 |
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15 | 0.2 ± 0.5 | -0.1 ± 0.5 |
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9 | -0.6 ± 0.5 | 2.7 ± 0.5 |
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6 | -1.6 ± 0.4 | 1.3 ± 0.4 |
The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3 | -2.1 ± 0.4 | -0.3 ± 0.4 |
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15 | 0.5 ± 0.2 | 0.4 ± 0.2 |
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15 | 0.6 ± 0.2 | 0.6 ± 0.2 |
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9 | 0.4 ± 0.2 | 1.5 ± 0.2 |
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6 | 0.1 ± 0.2 | 1.2 ± 0.2 |
The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3 | -0.7 ± 0.2 | 0.3 ± 0.2 |
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15 | -0.3 ± 0.1 | 0 ± 0.1 |
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15 | -0.2 ± 0.1 | -0.1 ± 0.1 |
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9 | -0.2 ± 0.1 | 0.1 ± 0.1 |
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6 | -0.3 ± 0.1 | 0.1 ± 0.1 |
The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3 | -0.2 ± 0.1 | -0.1 ± 0.1 |
The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse). Responders are defined as those patients with a CGI-I of 1 or 2.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15 | 18 | 21 |
The CGI-S measures the participants severity of illness on an ordinal scale ranging from 1 (normal) to 7 (extremely ill). At Month 15 participants were categorised to 'Improved' (\>1 category improvement), 'Unchanged' or 'Worsened' (\>1 category worsening).
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Improved | 4 | 3 |
| Essentially unchanged | 200 | 191 |
| Worsened | 5 | 4 |
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15 | -1 ± 0.3 | -0.5 ± 0.3 |
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9 | -1.1 ± 0.3 | 0.3 ± 0.3 |
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6 | -1.2 ± 0.3 | 0.2 ± 0.3 |
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3 | -1 ± 0.3 | -0.3 ± 0.3 |
The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15 | -0.4 ± -0.4 | 0.3 ± 0.3 |
The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9 | -0.5 ± -0.5 | 1.4 ± 1.4 |
The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15 | 0 ± 0 | 0 ± 0 |
The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9 | 0 ± 0 | 0 ± 0 |
The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15 | 0 ± 0 | 0 ± 0 |
The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
| Units on a scale | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9 | 0 ± 0 | -0.5 ± -0.5 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No risk of gambling | 146 | 133 |
| Risk of gambling | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No risk of gambling | 146 | 134 |
| Risk of gambling | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No risk of gambling | 146 | 134 |
| Risk of gambling | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No risk of gambling | 143 | 128 |
| Risk of gambling | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No risk of gambling | 145 | 132 |
| Risk of gambling | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive sexual behaviour | 146 | 133 |
| Compulsive sexual behaviour | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive sexual behaviour | 146 | 134 |
| Compulsive sexual behaviour | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive sexual behaviour | 146 | 134 |
| Compulsive sexual behaviour | 0 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive sexual behaviour | 143 | 126 |
| Compulsive sexual behaviour | 0 | 2 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive sexual behaviour | 145 | 131 |
| Compulsive sexual behaviour | 0 | 1 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive buying | 145 | 133 |
| Compulsive buying | 1 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive buying | 144 | 134 |
| Compulsive buying | 2 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive buying | 143 | 134 |
| Compulsive buying | 3 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive buying | 141 | 128 |
| Compulsive buying | 2 | 0 |
The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
| Participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| No compulsive buying | 143 | 132 |
| Compulsive buying | 2 | 0 |
The striatum beta-carbomethoxy-iodophenyl-tropane (beta-CIT) uptake was calculated as mean of the left and right caudate and putamen regions; measured by the Single-Photon Emission Computed Tomography (SPECT).
| Percentage change | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Percentage Change From Baseline in the Striatum Uptake at Month 15 | -15.1 ± 2.1 | -14.6 ± 2 |
| percentage of participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Haematocrit - decrease | 1.4 | 1.0 |
| Haemoglobin - decrease | 2.3 | 0.9 |
| MCV - increase | 0.5 | 0 |
| Sodium - decrease | 1.4 | 0.5 |
| Calcium - increase | 0 | 0.5 |
| Chloride - decrease | 0.9 | 0 |
| Phosphate - decrease | 1.0 | 0 |
| Phosphate - increase | 0.5 | 0 |
| percentage of participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| GGT - increase | 0.5 | 0 |
| Amylase - increase | 1.4 | 0 |
| percentage of participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Glucose - decrease | 0 | 2.2 |
| Glucose - increase | 3.6 | 0 |
| Cholesterol - increase | 1.4 | 2.9 |
| Blood Urea Nitrogen - increase | 0.9 | 0.5 |
| Creatinine - increase | 0.5 | 1.0 |
| Triglyceride - increase | 1.4 | 0 |
| Uric acid - increase | 0.5 | 0.5 |
| percentage of participants | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| Sinus bradycardia | 0 | 0.4 |
| Hypotension | 0 | 0.5 |
Collected over Onset date after the date of first dose up to 48 hours after last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Early Pramipexole | — | 25/261 (9.6%) | 172/261 (65.9%) |
| Delayed Pramipexole | — | 25/274 (9.1%) | 164/274 (59.9%) |
| Event | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| HallucinationPsychiatric disorders | 2/261 | 0/274 |
| Transient ischaemic attackNervous system disorders | 2/261 | 1/274 |
| Urinary tract infectionInfections and infestations | 0/261 | 2/274 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/261 | 2/274 |
| Bacterial infectionInfections and infestations | 1/261 | 0/274 |
| GastroenteristisInfections and infestations | 1/261 | 0/274 |
| InfluenzaInfections and infestations | 1/261 | 0/274 |
| Localised infectionInfections and infestations | 1/261 | 0/274 |
| Large cell carcinoma of the respiratory tract stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/261 | 0/274 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/261 | 0/274 |
| Event | Early Pramipexole | Delayed Pramipexole |
|---|---|---|
| NauseaGastrointestinal disorders | 62/261 | 49/274 |
| FatigueGeneral disorders | 36/261 | 38/274 |
| SomnolenceNervous system disorders | 36/261 | 21/274 |
| DizzinessNervous system disorders | 35/261 | 33/274 |
| HeadacheNervous system disorders | 20/261 | 28/274 |
| ConstipationGastrointestinal disorders | 19/261 | 28/274 |
| InsomniaPsychiatric disorders | 26/261 | 21/274 |
| Oedema peripheralGeneral disorders | 25/261 | 13/274 |
| Back painMusculoskeletal and connective tissue disorders | 24/261 | 18/274 |
| NasopharyngitisInfections and infestations | 19/261 | 24/274 |
| Age, Continuous(Years) | Early Pramipexole | Delayed Pramipexole | Total |
|---|---|---|---|
| Mean | 62.1 ± 10.1 | 62.9 ± 9.9 | 62.5 ± 10 |
| Sex: Female, Male(Participants) | Early Pramipexole | Delayed Pramipexole | Total |
|---|---|---|---|
| Female | 84 | 108 | 192 |
| Male | 177 | 166 | 343 |
The record gives a start of May 2006 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole